-
4301
725 Preliminary results of a prospective pilot study using CD8 ImmunoPET imaging to evaluate the immune response to radiation therapy (ELIXR)
Published 2023-11-01“…Journal for ImmunoTherapy of Cancer…”
Article -
4302
839 Transcriptomic profiling of T-cell populations in non-muscle invasive and muscle invasive bladder cancer
Published 2020-11-01“…Journal for ImmunoTherapy of Cancer…”
Article -
4303
1115 A novel lioblastoma model resistant to both innate and adaptive immunotherapy
Published 2023-11-01“…Journal for ImmunoTherapy of Cancer…”
Article -
4304
835 Harnessing the microbiota to increase response rates to immunotherapy
Published 2021-11-01“…Journal for ImmunoTherapy of Cancer…”
Article -
4305
308 GUCY2C-directed CAR-T cell therapy for upper GI cancers
Published 2023-11-01“…Journal for ImmunoTherapy of Cancer…”
Article -
4306
596 Armed myxoma virus demonstrates therapeutic activity in xenograft models
Published 2020-11-01“…Journal for ImmunoTherapy of Cancer…”
Article -
4307
17 Activity sensors for noninvasive monitoring of immune response and tumor resistance during immune checkpoint blockade therapy
Published 2020-11-01“…Journal for ImmunoTherapy of Cancer…”
Article -
4308
14 Humanized TFR1/CD71 knockin mouse model enables in vivo assessment of TFR1-targeted antibody therapies for cancer and beyond to across the blood-brain barrier
Published 2023-11-01“…Journal for ImmunoTherapy of Cancer…”
Article -
4309
622 Immune phenotype and iFRET functional analysis are biomarkers of response to neoadjuvant intralesional therapy for high risk stage II melanoma
Published 2023-11-01“…Journal for ImmunoTherapy of Cancer…”
Article -
4310
831 E3 ubiquitin ligase Cbl-b deficient CD8+ T cells overcome Treg cell-mediated suppression through IFN-γ and induce robust anti-tumor immunity
Published 2020-11-01“…Journal for ImmunoTherapy of Cancer…”
Article -
4311
144 Novel public and tumor-wide neoantigens arising from clonal aberrant splicing events drive tumor-specific T-cell responses across diverse cancer types
Published 2023-11-01“…Journal for ImmunoTherapy of Cancer…”
Article -
4312
1509-G M2 macrophage-derived exosomal microRNA-21–3p promotes colorectal cancer progression via mediating FAM46C
Published 2023-11-01“…Journal for ImmunoTherapy of Cancer…”
Article -
4313
1166 Preclinical evaluation of lintuzumab-Ac225, a CD33 antibody radioconjugate targeting myeloid-derived suppressor cells
Published 2023-11-01“…Journal for ImmunoTherapy of Cancer…”
Article -
4314
265 ADI-925: an allogeneic off-the-shelf chimeric adapter (CAd) γδ T cell therapy targeting NKG2D ligand-expressing cancers
Published 2023-11-01“…Journal for ImmunoTherapy of Cancer…”
Article -
4315
223 Potent inhibition of PI3Kδ promotes enhanced T cell stemness and mitochondrial fitness
Published 2021-11-01“…Journal for ImmunoTherapy of Cancer…”
Article -
4316
Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types
Published 2022-10-01“…Journal for ImmunoTherapy of Cancer…”
Get full text
Article -
4317
Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity
Published 2024-03-01“…Journal for ImmunoTherapy of Cancer…”
Get full text
Article -
4318
Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events
Published 2022-10-01“…Journal for ImmunoTherapy of Cancer…”
Get full text
Article -
4319
892 Non-redundant mechanisms of resistance to immunotherapy and radiotherapy converge on innate immunity
Published 2023-11-01“…Journal for ImmunoTherapy of Cancer…”
Article -
4320
395 Enhancement of bispecific T cell engagers (bispecific TCE) killing potency in AML with the neximmune artificial immune modulation (AIM™) adoptive cell therapy (ACT) T cells
Published 2023-11-01“…Journal for ImmunoTherapy of Cancer…”
Article